In the present study, TNF -gene ± transduced B78 melanoma cells ( B78 / TNF ) were used as a vaccine and combined with interleukin ( IL ) -12 in the treatment of B78 melanoma -bearing mice. The combined administration of genetically modified melanoma cells and IL -12 induced specific protective antitumor immunity resulting in a decreased rate of the tumor take following a rechallenge with parental B78 cells. When used therapeutically, intratumoral injections of irradiated B78 / TNF melanoma cells and IL -12 exerted strong antitumor effects and led to complete regression of established tumors in 50% of mice. Injections of irradiated B78 / TNF cells alone did not influence tumor development and IL -12 itself significantly delayed tumor growth but without curative effect. FACS analysis of parental B78 melanoma cells and its B78 / TNF genetically modified variant showed that a proportion of cells of both cell lines expressed B7 -1 ( CD80 ) costimulatory molecule and that the expression of this molecule was increased during incubation with IFN -. Moreover, IFN -markedly augmented expression of major histocompatibility class ( MHC ) class I and II molecules on B78 / TNF cells that were primarily MHC class I and II negative with no substantial effect on MHC -negative parental B78 melanoma. IFN -also synergized in cytostatic / cytotoxic effects with TNF -against B78 melanoma in vitro. Lymphocyte depletion studies in vivo showed reduction of the antitumor response in mice treated with anti -NK monoclonal antibodies ( mAbs ) as well as in mice treated with anti -CD4 + anti -CD8 mAbs. The results suggest that, when used therapeutically, IL -12 and a vaccine containing TNF -gene ± transduced tumor cells may reciprocally augment their overall antitumor effectiveness by facilitating development of systemic antitumor immunity and by stimulating local effector mechanisms of the tumor destruction. Cancer Gene Therapy ( 2000 ) 7, 1581 ± 1590
T he use of vaccines containing tumor cells genetically engineered to produce certain cytokines is an attractive strategy to enhance antitumor response. 1 ± 3 Cytokines secreted by genetically modified tumors, including TNF-, may trigger an efficient antitumor immunity in experimental animals and elicit immunologic memory that inhibits development of the tumor after a challenge with parental tumor cells. 4 ± 6 However, when used therapeutically in tumor-bearing animals, effectiveness of vaccines consisting of cytokine -producing tumor cells is far from expectations. This holds true for TNF -gene ± modified tumor cells.
Secretion of TNF -( a cytokine with apparent antitumor activity ) by engineered tumor cells was associated with low tumorigenicity of these cells and induced some protective effect but was found ineffective in eradication of established tumors. 4, 7, 8 In attempts to augment weakly effective tumor cell -or antigen-based vaccines, various agents with adjuvant activities have been used in conjunction. 4,9 ± 11 Interleukin ( IL ) -12 is of interest in this context as it displays adjuvant potential 12, 13 and stimulates strong antitumor reactions via activation of NK cells 14 and induction of cytotoxic T lymphocytes. 15 This cytokine promotes also the generation of T-helper type 1 (Th1 ) effector lymphocytes and stimulates these cells to secrete many cytokines, including IFN -. 16 ,17 IL -12 has been shown to significantly retard the growth of many murine tumors and to prolong the survival of experimental animals with various types of tumors.
In the present study, effectiveness of the therapy comprising vaccination with genetically modified, TNF±secreting tumor cells, in combination with IL -12 was studied in a melanoma model in mice.
MATERIALS AND METHODS

Mice
(C57BL /6ÂDBA /2 )F1 mice, hereafter called B6D2F1, 8 ± 12 weeks of age, were used in the experiments. Breeding pairs were obtained from the Inbred Mice Breeding Center of the Institute of Immunology and Experimental Medicine, Wroclaw, Poland. Mice were bred in a local animal facility and were kept in conventional conditions with full access to food and water during experiments.
Plasmid construction DCCMV ± TNF vector was generated by blunt end ligation of human TNF cDNA, excised as EcoRI fragment from the MSCV ±TNF retroviral vector (kindly provided by Dr. Robert G. Hawley, Holland Laboratories, Rockville, MA ) , into a filled SalI site of DCCMV 21 between the hCMV-IE promoter and the EMCV IRES -Neo cassette.
Production of recombinant retroviruses
Recombinant retroviruses were produced as replicationdefective pseudotyped particles carrying the amphotropic envelope protein using PA317 packaging cells ( American Type Culture Collection, Rockville, MA; CRL 9078 ) . Stable producer line was generated by transfection with vector plasmid DNA. Briefly, producer cells exporting helper-free amphotropic DCCMV ± TNF vector were generated by directly electroporating 5 g of ScaI-digested plasmid DNA into PA317 cells and selecting for transfectants by culturing in G418 -containing medium (500 g/ mL; Life Technologies ) for 3 weeks. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM ) with 4.5 g /L glucose ( Gibco BRL ± Life Technologies, Paisley, UK ) supplemented with 10% fetal calf serum (FCS ) (Gibco BRL ±Life Technologies ) at 378C in a humidified atmosphere of 5% CO 2 .
Tumor cells and transduction
The B -78 -H1 melanoma ( herein named B78 ), weakly immunogenic amelanotic subclone of murine B16 melanoma cell line, was kindly provided by Dr. L. H. Graf, Chicago, IL. Tumor cells were cultured in DMEM supplemented with 10% heat -inactivated FCS, antibiotics, 2 -mercaptoethanol (50 M ) and L -glutamine ( 2 mM ) (all from Gibco BRL ± Life Technologies ). Cells were maintained in 25-cm 2 tissue flasks ( Nunc, Roskilde, Denmark ) at 378C in a humidified atmosphere of 5% CO 2 and were passaged two to three times weekly.
Virus -containing supernatant was collected from confluent cultures of PA317 producer cells 16 hours after medium change. To generate stably transduced B78 cell line, vector supernatant was added to subconfluent culture in the presence of 8 g /mL polybrene for 4 hours at 378C. Three days later, the cells were selected in DMEM containing 500 g /mL G418. The selection was continued for 3 weeks and six single colonies were isolated and used for further characteristics.
Cytokines
Recombinant mouse IL -12 ( sp. act. 4.6Â10 6 U /mg protein ) was a generous gift from the Genetics Institute, Cambridge, MA. Murine recombinant IFN -(sp. act. 1Â10 7 U /mg ) was purchased from Genzyme. Recombinant human TNF -(sp. act. 3.2Â10 7 U /mg ) was provided by SERVA ( Heidelberg, Germany ) . For in vivo experiments, IL -12 was diluted with 0.1% bovine serum albumin ( BSA ) (Sigma, St. Louis, MO ) in PBS ( Gibco BRL ± Life Technologies ).
-( 4,5 -Dimethylthiazol -2 -yl ) -diphenyltetrasolium bromide ( MTT ) assay
The cytostatic /cytotoxic effect of IFN -on B78 or B78 / TNF melanoma cells in vitro was tested in a standard MTT assay, as described elsewhere. 20 Briefly, tumor cells were dispensed in a 96 -well flat -bottomed microtiter plate ( Nunc ) at a concentration of 2.5Â10 3 cells /100 L /well. Then IFN -and /or TNF -were added in 50 L, to give final concentrations of 2, 10, or 50 U /mL, and 1, 10, 100, 1000 ng/ mL, respectively. After an incubation period of 68 hours, MTT (Sigma) was added to each well. Four hours later the plates were centrifuged and 200 L of supernatant was carefully removed from wells and replaced with 200 L of acid ± DMSO. Absorbance was read on an ELISA reader ( SLT Labinstrument, Salzburg, Austria ), using a 550 -nm filter. The means and standard errors of the mean were determined for quadruplicate samples.
51
Cr -release assay and in vitro depletion of specific lymphocytes 51 Cr release from samples of the target cells incubated with 1% Triton X -100.
FACS analysis
Tumor cells were analyzed for B7 -1 molecules and major histocompatibility class (MHC ) I and II antigens by direct immunoflourescence assay. Cells were stained with fluorescein isothiocyanate ( FITC ) -labeled hamster antimouse B7 -1 monoclonal antibodies (mAbs) (PharMingen, San Diego, CA ) , FITC -labeled mouse anti± H -2K b mAbs ( Serotec, Oxford, England ), phycoerythrin -conjugated mouse anti -Ia mAbs ( Sigma -Biosciences, St. Louis, MO ) , or isotype -matched control mAbs for 30 min at 48C. Stained cells were washed and analyzed in a FACSCalibur flow microfluorocytometer ( Becton Dickinson, Sunnyvale, CA ) using CellQuest software ( Becton Dickinson ). Fluorescence profiles were generated by analysing 5000 cells and displayed as logarithmically increasing fluorescence intensity versus cell numbers.
In vivo experiments
B78 or B78 /TNF melanoma cells were injected into the footpad of the right hind limb at the dose of 1Â10 6 cells in 20 l PBS. Mice were treated intratumorally (i.t. ) with IL -12 at a daily dose of 0.1 g for 7 days, starting from day 7 after tumor-cell inoculation. In experiments on the antitumor effects of IL -12 and TNF -±secreting B78 / TNF cells, mice with established B78 melanoma were treated i.t. with 1Â10 6 viable irradiated (4500 rads ) B78 / TNF cells on days 3, 13, and 23 and with IL-12 ( 0.1 g) on days 6 ± 10, 16± 20, and 26 ± 30. Each injection of IL -12 or irradiated B78 / TNF cells was parallelled by i.t. injections of 0.1% BSA ± PBS into mice from the control groups. Local tumor growth was determined by measuring the diameter of the footpad (anterior ±posterior dimension ) with calipers every 3 ±4 days, starting from day 7 following inoculation of tumor cells. Tumor size was calculated according to the formula: tumor diameter = (diameter of footpad with growing tumor ) À (diameter of nontreated contralateral footpad) .
In some experiments, mice that experienced complete tumor regression were rechallenged with 1Â10 5 live nontransduced B78 melanoma cells or Lewis lung carcinoma ( LL / 2) . 20 Lymphocyte depletion studies in vivo Hybridoma cell lines: PK -136 (anti -NK1.1 ), GK -1.5 ( anti -CD4 ), and 53 ±6.72 (anti -CD8 ) were obtained from American Type Culture Collection. Monoclonal rat antibodies were produced using CellMax Quad System (Cellco Incorporated, Germantown, MA ) , according to manufacturer protocol. Lymphocyte subsets were ablated in mice with induced protective immunity ( vaccinated with B78 / TNF cells and treated with IL -12, as shown in Table 2 ) and rechallenged with 1Â10 5 parental B78 melanoma cells. To deplete specific lymphocytes mice were injected intraperitoneally (i.p. ) with anti -CD4, anti -CD8, anti -NK1.1 mAbs or control rat IgG (0.5 mg /injection /mouse) on days À 8, À 4, 0, +4, and + 8 relative to inoculation of B78 melanoma cells. This protocol was adopted from Coughlin et al 22 ( with slight modifications ) and depleted 95% specific lymphocyte subsets.
Statistical analysis
Differences between samples in tests in vitro and differences in tumor diameter in experiments in vivo were analyzed for significance by Student's t test (two-tailed ) . In some in vivo experiments, to analyze tumor-take rate after the rechallenge with B78 melanoma cells as well as to assess differences between animal groups as to proportions of dead mice, mice with tumor, and cured animals, the 2 test was used. In lymphocyte-depletion studies in vivo, differences between groups were assessed by nonparametric Mann -Whitney U test.
RESULTS
Characteristics of TNF -gene ± transduced tumor cells
B78 melanoma cells were transduced with TNF -expression vector as described in Materials and Methods. TNFproduction by transduced clones was determined by ELISA. Clone B78 /TNF --3 that produced the highest amounts of TNF -( 1955 pg/5Â10 5 cells /ml /24 h) was denoted B78 / TNF and used in experiments described below. TNFproduction remained stable over time in cultures of B78 / TNF melanoma cells ( data not shown) and the rate of proliferation of these cells was comparable to parental B78 cell line. To determine the stability of TNF -transduction in vivo, mice were injected with 10 6 B78 /TNF cells and 19-day tumors were removed, dissected, and enzymatically treated to obtain single-cell suspension for in vitro cultures. After three in vitro passages, TNF -production by recultured B78 /TNF cells was comparable to that in primary cultures (2295 pg /5Â10 5 cells / mL / 24 h ). Ability of TNF -production was also preserved in irradiated B78 /TNF cells ( 4500 rads ) used as vaccines in in vivo experiments ( 1582 pg /5Â10 5 cells /mL /24 h) .
In vivo growth of B78 and B78 / TNF tumors treated with IL -12 Figure 1 shows the results of experiments in which the growth of unmodified B78 -or B78 /TNF melanomabearing mice were treated for 7 days with 0.1 g IL-12.
When compared with parental cell line, B78 /TNF tumors grew more slowly. As expected, transduction of B78 cells with gene for TNF -rendered them extremely susceptible to treatment with IL -12 and, while modest delays in tumor development were observed in IL -12 ±treated mice with B78 melanoma ( P <.01, starting on day 14 ) (Fig Figure 1 . Effect of IL -12 on the growth of B78 melanoma or its TNF -± secreting subclone ( B78 / TNF ) . Seven days after inoculation of 1Â10 6 B78 ( A ) or B78 / TNF ( B ) tumor cells into the footpad of the right hind limb mice were treated i.t. with 0.1 g IL -12, daily for seven consecutive days ( thick lines ) . Tumor diameter is expressed as mean SEM; groups contained six to seven mice. 6 live B78 / TNF cells ( day 0 ) followed by seven i.t. injections of 0.1 g IL -12 on days 7 ± 13 ( such a treatment induces tumor eradication in 100% of mice, as shown in Figure 1 ) . On day 21 mice were rechallenged with 1Â10 5 parental B78 melanoma cells either into the footpad of the same limb or into the footpad of contralateral limb; control mice were injected with 1Â10 5 parental B78 melanoma cells with no previous treatment. Fifty days after the rechallenge, no tumor growth was observed in six of the seven, three of the six, and none of the seven mice, respectively ( P < .01, by 1A ) , in similarly treated mice with TNF -±secreting B78 /TNF melanomas complete rejection of the tumor was shown (Fig 1B ) . To determine whether regressions of B78 /TNF melanoma in mice treated with IL-12 would produce local and/ or systemic antitumor immunity, mice previously injected with B78 / TNF cells and cured due to IL -12 administration on days 7 ±13 were rechallenged with 1Â10 5 cells of parental B78 melanoma or with 1Â10 5 cells of Lewis lung carcinoma (a syngeneic cell line that shows no cross -reactivity with B78 melanoma ) ( Fig 2 ) . The rechallenge was performed 7 days after the last dose of IL-12, either into the footpad of the limb in which the primary B78 /TNF melanoma regressed or into the contralateral limb. As shown in Figure 2A , IL -12-induced eradication of the TNF -±secreting B78 /TNF melanoma led to generation of a potent local antitumor immunity ( in six of the seven mice challenged at the site of primary tumor regression no tumor developed on day 50 after the challenge ) and also, to a lesser extent, to activation of systemic protection mechanisms (no tumor take in the contralateral limb was observed in three of the six mice ) ( P< .01, by 2 test ) . No differences in tumor take were observed when mice were rechallenged, in an analogous experimental setting, with Lewis lung carcinoma (Fig 2A ) .
Effect of treatment with TNF -gene ± modified tumor vaccine and / or IL -12 on the growth of B78 melanoma
To evaluate whether vaccination with TNF -gene± modified B78 cells have therapeutic activity, B78 melanoma -bearing mice were treated i.t. with irradiated TNFgene ± modified B78 cells (1Â10 6 live cells on days 3, 13, and 23) . As shown in Figure 3 and Table 1 , no differences were found between controls and vaccine -treated mice. In contrast, three cycles of i.t. IL -12 injections (0.1 g on days For clarity, the data concerning these two groups are not presented in the figure but are discussed in Results. Further details concerning the experiment are given in Table 1 . Tumor diameter is expressed as mean SEM; groups contained 9 ± 10 mice. 6 ±10, 16± 20, and 26 ± 30) led to a marked inhibition of B78 melanoma development ( Fig 3 ) . However, the strongest antitumor effect was observed in mice treated with both irradiated B78 /TNF cells and IL -12. Significantly smaller tumors were found in the group of double -treated mice not only when compared with controls or vaccine -treated mice but also in comparison with mice injected with IL -12 ( mean tumor diameter ( MTD ) SE on day 44: 2.1 0.8 vs 3.2 0.4, P < .05) . More importantly, 50% of double -treated mice experienced no regrowth of the tumor on day 100 ( and in fact in longer observation period ) whereas 80% of mice from the``IL -12 group'' died before that day, and in the remaining 20% of mice tumors grew progressively (Table 1) (P <.05, by 2 test ). Two of five cured mice from the former group were able to reject a rechallenge with 1Â10 5 live B78 cells in the footpad of the contralateral limb performed 2 months after the treatment, suggesting that tumor eradication induced by vaccination with TNFgene ±modified B78 cells combined with IL -12 resulted in the induction of a long -lasting immunologic systemic memory.
To assess the advantage of TNF -gene ± modified B78 cells over wild -type tumor cells in the vaccine -based therapy combined with IL -12, mice with B78 melanoma were treated with irradiated B78 cells and IL -12 in the same treatment schedule as that where TNF -±secreting B78 / TNF cells were used with IL -12. This treatment induced significant retardation of the tumor growth when compared to the treatment with IL -12 alone ( MTD SE on day 44: 1.7 0.4 vs 3.2 0.4, P <.05, data not shown ). However, in long -term evaluation (on day 100) , no benefit of using parental B78 cell vaccine with IL -12 was observed over treatment with IL -12 alone (P > .05, by 2 test, data not shown) . ( Fig 2A ) Ð only one of eight mice (13%) experienced tumor growth after a rechallenge with parental melanoma cells ( Table  2 ). Depletion of NK cells markedly reduced this effect Ð tumor developed in majority of NK -depleted mice ( four of five mice, 80%, P < .05) . In contrast, neither anti -CD4 nor anti -CD8 mAbs, when administered alone, influenced the rate of tumor take but, interestingly, the combined depletion of CD4 + and CD8 + cells substantially impaired the protective effect of the vaccine+ IL -12 ( tumor developed in four of the five mice treated with both mAbs, 80%, P <.05 ) ( Table 2) .
Depletion of NK cells in vitro reduces cytotoxic effect of splenocytes from mice treated with B78 / TNF cells and IL -12
To shed more light on the role of specific lymphocyte subsets in the antitumor effect of B78 /TNF melanoma vaccine and IL -12, splenocytes from B78 /TNF melanoma +IL -12 ± treated mice, depleted in vitro of NK, CD4, or CD8 cells were incubated with YAC -1 or B78 target cells. Cytotoxic activity against NK -susceptible YAC -1 cells in mice injected with B78 / TNF cells+ IL -12 was significantly higher than that in control mice (data not shown ). This activity was markedly reduced after depletion of NK cells ( Fig 4) . In contrast, no cytotoxic effect of splenocytes, either untreated or depleted of NK, CD4 or CD8 cells, was found against B78 melanoma (Fig 4 ) .
IFN -synergizes with TNF -in the cytostatic / cytotoxic effect against B78 cells
In our previous studies we found synergistic cytostatic / cytotoxic effect of TNF -and IFN -, both in vitro and in vivo, on MmB16 melanoma. 23 We assumed, therefore, that TNF -released by B78 / TNF could synergize with IL -12-induced IFN -20 in our therapeutic model on B78 melanoma. This hypothesis was supported by results of in vitro experiments in which potentiation of the cytostatic /cytotoxic effect against B78 melanoma cells was observed during incubation with IFN -and TNF - ( Fig 5) . For example, viability of B78 cells incubated with 100 ng/ mL TNF - ( noninhibitory concentration) and 50 U / mL IFN -( concentration that inhibited viability by 22% ) was inhibited by 50% (Fig 5) .
Expression of B7 -1 ( CD80 ) , MHC class I and II molecules on B78 and B78 / TNF melanoma cells incubated with IFNAs illustrated in Figure 6 , a proportion of B78 and B78 / TNF melanoma cells constitutively express B7 -1 costimulatory molecules (10.7% and 26.9% of cells, respectively ); this expression was further increased when cells were cultured with 20 U /mL IFN -for 48 hours ( to 22.1% and 37.7%, respectively ). In contrast, neither B78 nor B78 /TNF melanoma cells expressed substantial MHC class I and II molecules. Most strikingly, while culturing with IFN -had a negligible effect on MHC class I and II expression on B78 melanoma cells, the same culture conditions markedly influenced both MHC class I and II expression on B78 / TNF cells ( 19.7% MHC class I positive and 19.4% MHC class II positive B78 /TNF cells were found at the end of incubation ).
DISCUSSION
In the present study we have shown that vaccination of tumor-bearing mice with tumor cells transduced with the TNF -gene ( B78 /TNF ) in combination with IL -12 have a strong therapeutic effect in a B78 melanoma model, more potent than when each agent was used alone ( Fig 3) . The combined treatment eradicated completely B78 melanoma in a significant proportion (50% ) of mice.
The TNF -gene was successfully introduced into cells of many murine tumor cell lines leading to a significant increase in their immunogenicity. 7, 8, 24 When compared with parental cells, tumor cells transduced with the TNF -gene were found to grow more slowly or even to regress, and induced in some cases protection against a subsequent challenge with unmodified tumor cells. 4, 7, 8, 24, 25 However, despite the direct evidence of activation of CD4 + and CD8 + T cells by TNF -± producing tumor cells, 13, 24 there has been no data on therapeutic effects of vaccination with such engineered tumor cells. Our present studies are consistent with studies of other investigators in showing no benefit of using TNF -gene ± transduced B78 cells alone in the treatment of established tumors.
TNF -exerts direct cytostatic /cytotoxic effects on cells of many tumor cell lines. However, it seems improbable that the amount of TNF -released by irradiated B78 /TNF injected at the site of primary tumor was sufficiently high to kill tumor cells directly and influence significantly tumor growth in mice treated with both vaccine and IL -12. Rather, small amounts of TNF -that were continuously released locally initiated inflammatory reaction, which together with effector mechanisms induced by additional provision of IL-12 allowed the development of efficient antitumor response. As shown in Figure 2A , the combined treatment with TNFgene ±transduced tumor cells and IL -12 induced not only local effect but also systemic immunity because some mice that experienced regressions of B78 /TNF melanoma due to treatment with IL -12 were found to be resistant to subsequent challenge with a wild -type B78 melanoma.
The following mechanisms explaining the antitumor effect of the combined treatment with a vaccine, containing TNF±releasing tumor cells, and IL -12 could be proposed.
( a) A proportion of B78 / TNF cells expressed B7 -1 molecules on their surface and, as shown in Figure 6 , this expression was further increased during a 48 -hour incubation with IFN -. More importantly, incubation with IFNinduced a significant increase in expression of MHC class I and II on B78 /TNF cells. IL -12 has been recognized as a potent stimulator of IFN -production 16, 20 and recently, the synergistic effect of IFN -and TNF -on B7 -1 expression has been reported. 26 One may therefore expect that IFN -, which was released following administration of IL -12 at the site of previously injected TNF -±secreting B78 /TNF cells, could in our model augment immunogenicity of B78 / TNF tumor cells and facilitate induction of T-cell response. Although we do not provide direct evidence for the proposed way of induction of specific immunity, a report by Coughlin et al, 22 showing the synergistic effects of IL-12 and tumor cells engineered to express B7 -1 molecule in induction of the antitumor immunity, supports such a hypothesis. Furthermore, our lymphocyte-depletion studies demonstrating impairment of protective anti -B78 immunity following administration of anti -CD4 +anti -CD8 mAbs ( Table 2) suggest that both T-cell subsets are required for the therapeutic effect of B78 /TNF vaccine+ IL -12 in our model. Lack of specific anti -B78 cytotoxicity by splenocytes from mice treated with B78 /TNF cell + IL -12 (Fig 4) is partly consistent with our depletion studies in vivo that showed insufficiency of CD8 + T-cell depletion in the abolition of protective immunity ( Table 2 ) . Altogether, these results suggest that mechanisms of specific T-cell -dependent response against B78 melanoma are not very potent and, possibly, operate mainly locally. Additional studies ( for example using lymph node lymphocytes or immunohistochemistry ) are needed to define the exact role of CD4 + and CD8 + T cells in the local tumor destruction. ( b) IL-12 stimulates effector functions of NK cells and could lead to their enhanced activation in the periphery. 14, 27 Furthermore, IL -12 stimulates local accumulation of NK cells. 19 These data together with the results of our NK -celldepletion studies in vivo ( Table 2 ) and in vitro ( Fig 4 ) show that NK cells may be important but not the only effectors mediating the antitumor effects during the therapy based on B78 /TNF melanoma vaccine and IL-12.
( c) One of the properties of TNF -is a strong chemotactic effect on monocytes and neutrophils. 8, 28, 29 It is probable, therefore, that TNF -released from B78 /TNF melanoma cells and IL -12 injected at the tumor site could induce accumulation of the abovementioned effectors. Because IFNstrongly stimulates tumoricidal activity of macrophages, 23, 30 one may assume that nonspecific killing of tumor cells by these cells could contribute to the overall local antitumor effect in the course of the combined treatment.
( d) Antitumor activity of the tumor-cell -based vaccine +IL -12 in our model could be also attributed to a direct synergistic cytostatic / cytotoxic effect of TNF -and IFNagainst B78 melanoma cells 23 ( Fig 5) as well as to the cytokine-related inhibition of angiogenesis. 31 In our previous studies we have shown inhibition of the tumor-cell -induced angiogenesis in mice treated with both TNF -and IL -12. 20 The effectiveness of IL -12 and tumor-cell -based vaccines in the treatment of established tumors have been tested in several recently published reports. In two of them, IL -2 gene ±transduced tumor cells were used in conjunction with IL -12 to treat glioma 32 or colon adenocarcinoma. 33 In both studies the combined therapy produced better results than the treatment with either agent alone and led to a long -term survival of double -treated mice. In another study genetically engineered tumor cells expressing B7 -1 and ICAM -1 were combined with IL -12 to treat glioma in mice. 34 Like in the two above cited reports, vaccination with genetically modified tumor cells plus IL -12 was more effective in tumor eradication than either a vaccine or IL-12 alone. Recently, Taniguchi et al 35 reported, in a similar therapeutic approach to ours, a synergy in the antitumor effects following simultaneous application of TNF -gene ± transduced tumor cells and IL -12. However, the tumor model that was used in studies by Taniguchi et al differed essentially from that in our investigations. They used highly immunogenic methylcholantrene -induced fibrosarcoma whereas our B78 melanoma is weakly immunogenic. Accordingly, they showed an important role of CD8 + T cells in the antitumor response in their model. 35 In contrast, it seems that nonspecific, NK -cell -dependent mechanisms predominate in the therapeutic effects against B78 melanoma (Table 2, Figure 4 ) in our studies.
IL -12 is a cytokine of proved antitumor effects that was demonstrated in many tumor models in experimental animals. 18 ± 20 However, in preliminary clinical studies this cytokine was found toxic in certain treatment schedules and caused life -threatening side -effects in some patients. 36 Our present studies and the above -discussed reports of other authors demonstrate potentiation of the antitumor efficacy of IL -12 by tumor vaccines without augmenting toxicity. Vaccination with TNF -gene ±modified tumor cells in combination with IL -12, as shown in our melanoma model, could be especially effective against weakly immunogenic and /or MHC -negative tumors by facilitating induction of specific antitumor immunity and by synergizing in activation of nonspecific mechanisms of tumor destruction.
